Mark Wainberg

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. doi request reprint The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
    Melissa Wares
    Lady Davis Institute for Medical Research, McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 11:7. 2014
  2. pmc What if HIV were unable to develop resistance against a new therapeutic agent?
    Mark A Wainberg
    Departments of Medicine and Microbiology, Jewish General Hospital, McGill University, Montreal, QC, Canada
    BMC Med 11:249. 2013
  3. pmc Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention
    Ravindra K Gupta
    Division of Infection and Immunity, University College, 90 Gower St, London WC1E 6BT, UK
    Retrovirology 10:82. 2013
  4. pmc Obituary: Kuan-Teh Jeang
    Ben Berkhout
    Department of Medical Microbiology, Laboratory of Experimental Virology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center, University of Amsterdam, Meibergdreef 15, Amsterdam, 1105 AZ, The Netherlands
    Retrovirology 10:28. 2013
  5. pmc Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity
    Diane N Singhroy
    McGill University AIDS Centre, Lady Davis for Medical Research, Jewish General Hospital, 3755 Cote Sainte Catherine, Montreal, QC, H3T 1E2, Canada
    Retrovirology 10:73. 2013
  6. pmc Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
    Thibault Mesplede
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 10:22. 2013
  7. pmc Multiple choices for HIV therapy with integrase strand transfer inhibitors
    Francois Raffi
    University Hospital of Nantes, France
    Retrovirology 9:110. 2012
  8. doi request reprint The development of novel HIV integrase inhibitors and the problem of drug resistance
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis for Medical Research, Jewish General Hospital, Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    Curr Opin Virol 2:656-62. 2012
  9. pmc Gender-sensitive reporting in medical research
    Shirin Heidari
    International AIDS Society, Geneva, Switzerland
    J Int AIDS Soc 15:11. 2012
  10. doi request reprint The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition
    Veronique Michaud
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, 3755 Cote Ste Catherine Rd, Montreal, Quebec, H3T 1E2, Canada
    Pharmacol Rev 64:803-33. 2012

Research Grants

Detail Information

Publications114 found, 100 shown here

  1. doi request reprint The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
    Melissa Wares
    Lady Davis Institute for Medical Research, McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 11:7. 2014
    ..The M50I polymorphism is also observed in 10-25% of INSTI-naïve patients and has been reported in combination with R263K in a patient failing treatment with RAL...
  2. pmc What if HIV were unable to develop resistance against a new therapeutic agent?
    Mark A Wainberg
    Departments of Medicine and Microbiology, Jewish General Hospital, McGill University, Montreal, QC, Canada
    BMC Med 11:249. 2013
    ..This has led to speculation that DTG might have a higher genetic barrier for the development of drug resistance than the other compounds that are used in therapy...
  3. pmc Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention
    Ravindra K Gupta
    Division of Infection and Immunity, University College, 90 Gower St, London WC1E 6BT, UK
    Retrovirology 10:82. 2013
    ....
  4. pmc Obituary: Kuan-Teh Jeang
    Ben Berkhout
    Department of Medical Microbiology, Laboratory of Experimental Virology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center, University of Amsterdam, Meibergdreef 15, Amsterdam, 1105 AZ, The Netherlands
    Retrovirology 10:28. 2013
    ..Many of us came to know Teh as an energetic and gifted scientist for whom we had much respect and affection...
  5. pmc Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity
    Diane N Singhroy
    McGill University AIDS Centre, Lady Davis for Medical Research, Jewish General Hospital, 3755 Cote Sainte Catherine, Montreal, QC, H3T 1E2, Canada
    Retrovirology 10:73. 2013
    ..e. Tat, Rev and nucleocapsid (NC). PRMT6 also displays automethylation capacity but the role of this post-translational modification in its antiretroviral activity remains unknown...
  6. pmc Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
    Thibault Mesplede
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 10:22. 2013
    ..Additional experiments reported here provide a plausible explanation for the absence of reported dolutegravir resistance among integrase inhibitor-naïve patients to date...
  7. pmc Multiple choices for HIV therapy with integrase strand transfer inhibitors
    Francois Raffi
    University Hospital of Nantes, France
    Retrovirology 9:110. 2012
    ....
  8. doi request reprint The development of novel HIV integrase inhibitors and the problem of drug resistance
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis for Medical Research, Jewish General Hospital, Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    Curr Opin Virol 2:656-62. 2012
    ....
  9. pmc Gender-sensitive reporting in medical research
    Shirin Heidari
    International AIDS Society, Geneva, Switzerland
    J Int AIDS Soc 15:11. 2012
    ..Journal editors are also promoters of ethical research and adequate standards of reporting, and requirements for inclusion of gender analyses should be integrated into editorial policies as a matter of urgency...
  10. doi request reprint The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition
    Veronique Michaud
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, 3755 Cote Ste Catherine Rd, Montreal, Quebec, H3T 1E2, Canada
    Pharmacol Rev 64:803-33. 2012
    ....
  11. pmc Novel therapeutic strategies targeting HIV integrase
    Peter K Quashie
    McGill University AIDS Centre, Lady Davis Institute, Montreal, Canada
    BMC Med 10:34. 2012
    ..This review considers the history of the clinical development of HIV integrase inhibitors, the development of antiviral drug resistance and the need for new antiviral compounds...
  12. pmc The viral protein Tat can inhibit the establishment of HIV-1 latency
    Daniel A Donahue
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 86:3253-63. 2012
    ....
  13. pmc Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir
    Peter K Quashie
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 86:2696-705. 2012
    ..Structural modeling suggested and in vitro IN-DNA binding assays show that the R263K mutation affects IN-DNA interactions...
  14. pmc The role of unintegrated DNA in HIV infection
    Richard D Sloan
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
    Retrovirology 8:52. 2011
    ..This review focuses on the role of unintegrated DNA in HIV infection and additionally considers the potential implications for antiviral therapy...
  15. pmc Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably?
    Rodney S Russell
    McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, H3T 1E2, Canada
    Retrovirology 1:23. 2004
    ....
  16. pmc New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu
    Anne Gatignol
    Lady Davis Institute for Medical Research, and Department of Medicine, Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
    Retrovirology 4:8. 2007
    ..Aspects of viral structure, virus-host interactions, antiviral defenses, drugs and vaccinations, and epidemiological aspects were discussed for HIV and HCV. Old and recent data on the flu epidemics ended this meeting...
  17. pmc Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection
    Guido van Marle
    Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
    Retrovirology 7:74. 2010
    ..It serves as a viral reservoir and host-pathogen interface in infection. This study examined whether different parts of the gut and peripheral blood lymphocytes (PBL) contain different drug-resistant HIV-1 variants...
  18. pmc Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes
    Richard D Sloan
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
    Retrovirology 7:44. 2010
    ..Infected cells bearing unintegrated DNA were assayed by flow cytometry in the GFP reporter cell line, Rev-CEM, for cell surface levels of CD4, CXCR4 and CCR5...
  19. pmc PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA
    Cédric F Invernizzi
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Sir Mortimer B, Davis Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    Retrovirology 3:93. 2006
    ..Since Tat is known to be asymmetrically arginine dimethylated by protein arginine methyltransferase 6 (PRMT6) in its arginine rich motif, we investigated whether the Rev protein could act as a substrate for this enzyme...
  20. pmc Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance
    Hong Tao Xu
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec H3T1E2, Canada
    Retrovirology 6:14. 2009
    ..We investigated the effects of mutations K65R and K65R plus M184V on enzymatic function and mechanisms of drug resistance in subtype C reverse transcriptase (RT)...
  21. pmc Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C
    Hong Tao Xu
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 7:80. 2010
    ....
  22. pmc Impact of the 16th International Conference on AIDS: can these conferences lead to policy change?
    Helene Gayle
    CARE USA, Atlanta, GA 30303, USA
    Retrovirology 4:13. 2007
    ..It is vital that scientists and policy-makers continue to be able to interact at these meetings as part of global efforts to combat the HIV epidemic...
  23. pmc The XVI International Conference on AIDS: the place to be!
    Mark A Wainberg
    Retrovirology 3:9. 2006
    ....
  24. pmc Recovery of fitness of a live attenuated simian immunodeficiency virus through compensation in both the coding and non-coding regions of the viral genome
    James B Whitney
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 4:44. 2007
    ..These findings indicate that viral reversion that overcomes a genetic bottleneck is not limited to a single pathway, and illustrates the remarkable adaptability of lentiviruses...
  25. pmc Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report
    Yudong Quan
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, H3T 1E2, Canada
    Retrovirology 5:43. 2008
    ....
  26. pmc Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes
    Tamara Bar-Magen
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 6:103. 2009
    ..Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes...
  27. pmc Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239
    James B Whitney
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada
    Retrovirology 3:96. 2006
    ..We also assessed the impact of these deletions upon viral infectiousness, replication kinetics and gene expression in cell lines and monkey peripheral blood mononuclear cells (PBMC)...
  28. pmc Tetherin restricts direct cell-to-cell infection of HIV-1
    Björn D Kuhl
    McGill University AIDS Center, Lady Davis Institute, Jewish General Hospital, Montreal, Canada
    Retrovirology 7:115. 2010
    ..Viral dissemination between T-cells can occur via cell-free transmission or the more efficient direct cell-to-cell route through lipid raft-rich virological synapses, to which tetherin localizes...
  29. pmc Time for gender mainstreaming in editorial policies
    Shirin Heidari
    Journal of the International AIDS Society, 1216 Cointrin, Geneva, Switzerland
    J Int AIDS Soc 14:11. 2011
    ..Editors' associations could play an essential role in facilitating a transition to improved standard editorial policies...
  30. pmc Journal of the International AIDS Society: an important step forward
    Mark A Wainberg
    International AIDS Society, Geneva, Switzerland
    J Int AIDS Soc 11:1. 2008
    ..ABSTRACT: This editorial welcomes readers to the launch of Journal of the International AIDS society...
  31. ncbi request reprint HIV-1 subtype distribution and the problem of drug resistance
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 18:S63-8. 2004
    ..This consideration notwithstanding, drug resistance is unlikely to become a more serious issue in developing than developed countries, and there is an urgency to make anti-HIV drugs available to all who are in need...
  32. pmc Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countries
    Jorge L Martinez-Cajas
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    J Int AIDS Soc 11:2. 2008
    ..abstract:..
  33. ncbi request reprint Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection
    Mark A Wainberg
    McGill University AIDS Center, Lady Davis Institute Jewish General Hospital, Montreal, QC, Canada
    Antivir Ther 10:13-28. 2005
    ..The successful development of new NRTIs will depend upon a thorough appreciation of these many and complex issues, not only among those involved in the design of clinical studies, but also those contributing to their review and conduct...
  34. pmc Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 49:1671-8. 2005
  35. pmc Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens
    Florence Doualla-Bell
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Int AIDS Soc 12:25. 2009
    ..abstract:..
  36. pmc HIV transmission should be decriminalized: HIV prevention programs depend on it
    Mark A Wainberg
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 5:108. 2008
    ..In fact, however, people should understand that such legal action, and the willingness of the courts to hear these cases, will only weaken the global battle against HIV transmission...
  37. pmc Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine
    Michel Ntemgwa
    McGill University AIDS Centre, Jewish General Hospital, 3755 Cote Ste Catherine Rd, Montreal, Quebec, Canada H3T 1E2
    Antimicrob Agents Chemother 51:3861-9. 2007
    ....
  38. pmc Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)
    Jorge L Martinez-Cajas
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Int AIDS Soc 12:11. 2009
    ..Attention to newer drug combinations, as well as baseline genotyping of non-B isolates, in well-designed longitudinal studies with long duration of follow up are needed...
  39. ncbi request reprint Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review
    Mark A Wainberg
    McGill University AIDS Center, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS Patient Care STDS 21:609-20. 2007
    ..Further research is required to clarify the relative importance of these mechanisms and ways in which they might be enhanced...
  40. pmc 25 years of HIV-1 research - progress and perspectives
    Mark A Wainberg
    McGill University AIDS Centre, Jewish General Hospital, chemin Cote Ste Catherine, Montreal, Quebec H3T 1E2, Canada
    BMC Med 6:31. 2008
    ..Here, we summarize, in brief, advances that have been achieved and provide some perspectives on future challenges...
  41. doi request reprint Perspectives on antiviral drug development
    Mark A Wainberg
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada
    Antiviral Res 81:1-5. 2009
    ..These topics will all play a pivotal role in drug development and the management of viral infections in the years to come...
  42. ncbi request reprint Is there any hope for AIDS?
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute, Sir Mortimer B Davis Jewish General Hospital, Montreal, Que
    Clin Invest Med 27:51-8. 2004
    ..There is an urgency to make anti-HIV drugs available to all who are in need, regardless of ability to pay...
  43. pmc Lack of effect of recombinant human growth hormone on the in vitro activities of antiretroviral drugs against human immunodeficiency virus type 1
    Mark A Wainberg
    McGill AIDS Center, Jewish General Hospital, Lady Davis Institute, 3755 Cote St Catherine Rd, Montreal, Quebec H3T 1E2, Canada
    Antimicrob Agents Chemother 48:2337-40. 2004
    ..r-hGH had no significant effect on either viral replication or the 50% inhibitory concentrations of these compounds...
  44. doi request reprint Transmission dynamics of the M184V drug resistance mutation in primary HIV infection
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    J Antimicrob Chemother 66:2346-9. 2011
    ..M184V in HIV-1 reverse transcriptase is among the most common mutations in patients failing antiretroviral therapy but is found only rarely in cases of transmitted drug resistance...
  45. ncbi request reprint The emergence of HIV resistance and new antiretrovirals: are we winning?
    Mark A Wainberg
    McGill University AIDS Centre, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montreal, Que, Canada H3T 1E2
    Drug Resist Updat 7:163-7. 2004
  46. ncbi request reprint Resistance issues with new nucleoside/nucleotide backbone options
    Mark A Wainberg
    McGill University AIDS Centre, Montreal, Canada
    J Acquir Immune Defic Syndr 37:S36-43. 2004
    ..This review summarizes the clinical implications of resistance profiles associated with new NRTI/NtRTI regimens in current use and in advanced clinical studies...
  47. ncbi request reprint Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Quebec, Canada
    Infect Disord Drug Targets 9:172-90. 2009
    ..The ability to sequence new therapies will be enhanced by availability of new antiretroviral drugs...
  48. pmc Jean-Luc Darlix: Renaissance scientist and retrovirologist par excellence
    Mark A Wainberg
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Retrovirology 8:59. 2011
    ..ABSTRACT: Jean-Luc Darlix was recently recognized with the first Retrovirology Lifetime Achievement Award on the occasion of his "retirement" symposium in Lyon...
  49. ncbi request reprint The role of Tat in HIV-1 replication: an activator and/or a suppressor?
    Chen Liang
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
    AIDS Rev 4:41-9. 2002
    ..This suppressor activity of Tat can restrict the premature reverse transcription of viral RNA in the cytoplasm and allows the viral genome to be packaged as intact RNA molecules...
  50. pmc In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
    Susan M Schader
    Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada
    Antimicrob Agents Chemother 56:751-6. 2012
    ....
  51. ncbi request reprint The impact of the M184V substitution on drug resistance and viral fitness
    Mark A Wainberg
    McGill University AIDS Centre, 3755 Chemin de la Cote Ste Catherine, Montreal, Quebec H3T 1E2, Canada
    Expert Rev Anti Infect Ther 2:147-51. 2004
    ..Processivity of the reverse transcriptase enzyme may be affected by mutations such as M184V, and this may be a major determinant of viral replication fitness...
  52. pmc Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression
    Marie Chloe Boulanger
    Terry Fox Molecular Oncology Group, Lady Davis Institute, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 79:124-31. 2005
    ..Our study demonstrates that arginine methylation of Tat negatively regulates its transactivation activity and that PRMT6 acts as a restriction factor for HIV replication...
  53. pmc Effects of a single amino acid substitution within the p2 region of human immunodeficiency virus type 1 on packaging of spliced viral RNA
    Rodney S Russell
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    J Virol 77:12986-95. 2003
    ..Taken together, our data demonstrate that selective packaging of viral genomic RNA is influenced by the MP2 mutation and that this represents a major mechanism for rescue of viruses containing the DeltaDIS deletion...
  54. pmc Transmission networks of drug resistance acquired in primary/early stage HIV infection
    Bluma G Brenner
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 22:2509-15. 2008
    ..In Quebec, half of PHIs represent clustered transmission events. This study ascertained the cumulative implications of clustering on onward transmission of drug resistance...
  55. pmc Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region
    Baode Xie
    McGill University AIDS Centre, Department of Medicine, Terry Fox Molecular Oncology Group, Lady Davis Institute, St Mortimer B Davis Jewish General Hospital, 3755 Cote Ste Catherine Rd, Montreal, Quebec H3T 1E2, Canada
    J Virol 81:4226-34. 2007
    ..Finding a way of inhibiting or stimulating PRMT6 activity might help to drive quiescently infected cells out of latency or combat HIV-1 replication, respectively...
  56. pmc Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor
    Tamara Bar-Magen
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    J Virol 84:9210-6. 2010
    ....
  57. pmc Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2
    Michel L Ntemgwa
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 53:708-15. 2009
    ..These results underscore potential differences in emergent drug resistance pathways in HIV-1 and HIV-2 and show that polymorphisms may influence the development of the resistance pathways that are likely to emerge...
  58. ncbi request reprint Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations
    Fernando A Frankel
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 21:665-75. 2007
    ..To determine the underlying biochemical mechanisms responsible for the diminished viral replicative capacity associated with K65R/M184V-containing viruses...
  59. pmc Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1
    Dan Turner
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 48:2993-8. 2004
    ..These substitutions and polymorphisms reflect different patterns of codon usage among viruses of different subtypes. However, the existence of different subtypes may only rarely affect patterns of drug resistance-associated mutations...
  60. pmc Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT
    Hugues Loemba
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 46:2087-94. 2002
    ..These findings suggest that RT genotypic diversity may influence the emergence of drug resistance...
  61. ncbi request reprint The R362A mutation at the C-terminus of CA inhibits packaging of human immunodeficiency virus type 1 RNA
    Xiaofeng Guo
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
    Virology 343:190-200. 2005
    ..These data suggest that one potential function for the C-terminal disordered sequence of CA in HIV-1 replication is to regulate HIV-1 RNA packaging...
  62. ncbi request reprint Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance
    Hugues Loemba
    McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
    Antiviral Res 56:129-42. 2002
    ..Further characterization of predicted CTL and T-helper anchor motifs and ARV-induced mutations in HIV-1 non-B subtype RTs is warranted...
  63. pmc Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture
    Daniel A Donahue
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 54:1047-54. 2010
    ..We discuss how stage-dependent inhibition helps to explain the unique viral load decay dynamics observed clinically with RAL...
  64. pmc Sequences downstream of the 5' splice donor site are required for both packaging and dimerization of human immunodeficiency virus type 1 RNA
    Rodney S Russell
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    J Virol 77:84-96. 2003
    ..We conclude that both the SL3 motif and GA-rich RNA sequences, located downstream of the 5' splice donor site, are required for efficient RNA packaging and dimerization...
  65. pmc Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag
    Xiaofeng Guo
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, 3755 Cote Ste Catherine Rd, Montreal, Quebec, Canada H3T 1E2
    J Virol 79:1803-12. 2005
    ..Based on the myristyl switch model, we propose that the M368A mutation inhibits Gag multimerization and, as a result, restricts the binding of Gag to cellular membranes...
  66. pmc Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture
    Marco Petrella
    McGill University AIDS Centre, Jewish General Hospital, Lady Davis Institute for Medical Research, 3755, Chemin de la Cote Ste Catherine, Montreal, Quebec H3T 1E2, Canada
    Antimicrob Agents Chemother 48:4189-94. 2004
    ..In contrast, neither ddI nor ddC was able to maintain M184V to the same extent as the other drugs after 10 weeks of tissue culture in mixtures of wild-type viruses and isolates containing M184V in different proportions...
  67. pmc The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates
    Karidia Diallo
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, McGill University, Montreal, H3T 1E2 Quebec, Canada
    Antimicrob Agents Chemother 47:2376-9. 2003
    ..Similarly, there was a marked delay in the emergence of mutations associated with APV resistance (I54 M/L/V) in subtype B viruses harboring M184V compared with paired WT viral isolates...
  68. pmc Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase
    Fernando A Frankel
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec H3T 1E2, Canada
    Antimicrob Agents Chemother 49:2657-64. 2005
    ..Finally, we confirmed previous findings that L74V-containing viruses display diminished replication capacity and that this is associated with reduced levels of synthesis of early reverse-transcribed viral DNA molecules...
  69. ncbi request reprint Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection
    Dan Turner
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 37:1627-31. 2004
    ..05). These findings suggest that both decreased viremia and viral fitness in the case of M184V-containing HIV-1 variants may impact on viral transmissibility...
  70. pmc Role of RNA in facilitating Gag/Gag-Pol interaction
    Ahmad Khorchid
    Lady Davis Institute for Medical Research and McGill AIDS Center Jewish General Hospital, McGill University, Montreal, Quebec, Canada H3T 1E2
    J Virol 76:4131-7. 2002
    ..When present only in Gag-Pol, this mutation has no effect upon complex formation. This result indicates that Gag-Pol may not interact directly with RNA but rather requires RNA-facilitated Gag multimerization for its interaction with Gag...
  71. ncbi request reprint Deletion of stem-loop 3 is compensated by second-site mutations within the Gag protein of human immunodeficiency virus type 1
    Liwei Rong
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    Virology 314:221-8. 2003
    ..Therefore, the positive effects of A11V and I12V on dimerization of the SL3-deleted RNA must have taken place at the maturation stage...
  72. doi request reprint Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1
    Dimitrios Coutsinos
    McGill University AIDS Center, Jewish General Hospital, Montreal, QC, Canada
    Antivir Chem Chemother 20:117-31. 2010
    ..This new study now further establishes the basis for differential occurrence of both K65R and thymidine analogue mutations (TAMs) between subtypes...
  73. pmc Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1
    Thomas A Toni
    McGill University AIDS Centre, Department of Medicine, and Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste Catherine Rd, Montreal, Quebec, Canada H3T 1E2
    Antimicrob Agents Chemother 54:907-11. 2010
    ..Thirty HIV-1 subtype C- and 26 subtype B-infected patients lacking K65R as determined by conventional sequencing methods were studied, and viral minority species were found in four HIV-1 subtype C samples...
  74. pmc The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity
    Hong Tao Xu
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    Antimicrob Agents Chemother 54:2401-8. 2010
    ....
  75. pmc Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations
    Maureen Oliveira
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 53:1683-5. 2009
    ..The original mutations were maintained by the presence of apricitabine but were lost when cultured without drug pressure...
  76. ncbi request reprint Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1
    Dan Turner
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
    J Antimicrob Chemother 53:53-7. 2004
    ..Interactions between different mutations may complicate the understanding of HIV drug resistance with regard to the likelihood of therapeutic success...
  77. ncbi request reprint The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses
    Xin Wei
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, McGill University, 3755 Chemin Cote Sainte Catherine, Montreal, Quebec, Canada H3T 1E2
    AIDS 16:2391-8. 2002
    ..To study the ability of HIV constructs containing the M184V substitution in reverse transcriptase (RT), which causes resistance to lamivudine, to evolve mutations that compensate for deletions within the HIV genome...
  78. ncbi request reprint Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis
    Xin Wei
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, H3T 1E2, Montreal, Quebec, Canada
    Virology 311:202-12. 2003
    ..These findings provide biochemical evidence that initiation of tRNA(Lys3)-primed DNA synthesis is an important rate-limiting step in reverse transcription that correlates with viral replication fitness...
  79. ncbi request reprint A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors
    Bluma Brenner
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 17:F1-5. 2003
    ..This study evaluates the prevalence of V106 (GTG) and 106M (ATG) codons in clinical isolates as well as the effects of V106M on resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI)...
  80. pmc Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1
    Karidia Diallo
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 46:2254-6. 2002
    ..These data suggest that the presence of ZDV amplifies differences in replication capacity between wild-type HIV-1 and the mutant variant...
  81. ncbi request reprint HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture
    Bluma G Brenner
    McGill University AIDS Centre, Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada
    AIDS 20:F9-13. 2006
    ..Genotypic diversity among HIV-1 subtypes and circulating recombinant forms (CRF) may lead to distinct pathways to drug resistance. This study evaluated subtype-related differences in the development of resistance in culture to tenofovir...
  82. pmc Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection
    Bluma G Brenner
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 76:1753-61. 2002
    ..These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence...
  83. ncbi request reprint High rates of forward transmission events after acute/early HIV-1 infection
    Bluma G Brenner
    McGill AIDS Centre Jewish General Hospital, Montreal, Canada
    J Infect Dis 195:951-9. 2007
    ..A population-based phylogenetic approach was used to characterize human immunodeficiency virus (HIV)-transmission dynamics in Quebec...
  84. ncbi request reprint Arginine methylation of the HIV-1 nucleocapsid protein results in its diminished function
    Cédric F Invernizzi
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Cote Sainte Catherine Road, Montreal, Quebec, Canada
    AIDS 21:795-805. 2007
    ..As Tat is known to be asymmetrically arginine dimethylated by protein arginine methyltransferase 6 (PRMT6) in its ARM, we investigated whether NC could also act as a substrate for this enzyme...
  85. pmc The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription
    Masanori Kameoka
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    J Virol 76:3637-45. 2002
    ..We hypothesize that the second activity, illustrating functional homology between Tat and NC, suggests a potential role for NC in the displacement of Tat during viral maturation...
  86. ncbi request reprint Spliced human immunodeficiency virus type 1 RNA is reverse transcribed into cDNA within infected cells
    Chen Liang
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada H3T
    AIDS Res Hum Retroviruses 20:203-11. 2004
    ..Therefore, spliced HIV-1 RNA molecules must have been reverse transcribed along with full-length viral RNA during infection...
  87. ncbi request reprint Translation of Pr55(gag) augments packaging of human immunodeficiency virus type 1 RNA in a cis-acting manner
    Chen Liang
    McGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    AIDS Res Hum Retroviruses 18:1117-26. 2002
    ..Taken together, our data demonstrate that cis translation of Pr55(gag) is needed for efficient packaging of HIV-1 RNA...
  88. ncbi request reprint Might the M184V substitution in HIV-1 RT confer clinical benefit?
    Marco Petrella
    McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS Rev 4:224-32. 2002
    ..There is a need for randomized clinical trials of this type in order to validate the potential benefit of maintenance of M184V and whether continued use of 3TC is the only means of attaining this objective...
  89. pmc Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs
    Dan Turner
    McGill University, Montreal, Quebec, Canada
    MedGenMed 7:69. 2005
    ..In conclusion, the G-->A transition was most prevalent in RT and PR among untreated patients. In contrast, A-->G was the most prevalent transition in patients treated with antiretroviral drugs...
  90. ncbi request reprint Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection
    Bluma Brenner
    McGill University AIDS Centre, Jewish General Hospital and McGill University Health Centre, Montreal, Quebec, Canada
    AIDS 18:1653-60. 2004
    ..This study characterizes the evolution of transmitted wild-type (WT) (n = 15), resistant (n = 10), and MDR (n = 6) infections. Long-term persistence of MDR infections (2-7 years), leading to one observed MDR superinfection is documented...
  91. pmc The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus
    James B Whitney
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    J Virol 76:8958-62. 2002
    ..We also observed that M184V significantly impaired the potential for both compensatory mutagenesis and reversion in these mutants both in cell lines and in peripheral blood mononuclear cells...
  92. ncbi request reprint Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
    Jean Pierre Routy
    Immunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    AIDS 18:2305-12. 2004
    ..A study of chronically infected (CI) patients, who represent potential HIV-1 transmitters, was carried out in order to ascertain biological factors associated with this trend change...
  93. pmc A structurally disordered region at the C terminus of capsid plays essential roles in multimerization and membrane binding of the gag protein of human immunodeficiency virus type 1
    Chen Liang
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    J Virol 77:1772-83. 2003
    ....
  94. ncbi request reprint HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors
    Mark A Wainberg
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 34:S2-7. 2003
    ..This paper summarizes current knowledge about the mutations in the reverse transcriptase gene of HIV-1 that are responsible for drug resistance and the mechanisms whereby drug resistance develops...
  95. pmc Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag
    Chen Liang
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    J Virol 76:11729-37. 2002
    ..Therefore, these four mutations must have prevented Gag from generating large complexes...
  96. ncbi request reprint HIV-1 drug resistance: can we overcome?
    Bluma G Brenner
    Lady Davis Institute for Medical Research, Jewish General Hospital, McGill AIDS Centre, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
    Expert Opin Biol Ther 2:751-61. 2002
    ..This review discusses the development and influence of known drug mutations on drug susceptibility versus viral fitness...
  97. pmc Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations
    Hong Tao Xu
    McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Cote Ste Catherine Rd, Montreal, Quebec H3T 1E2, Canada
    J Virol 85:11300-8. 2011
    ..Structural modeling shows that the addition of E138K to M184I/V promotes tighter dNTP binding...
  98. pmc Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef
    Richard D Sloan
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, H3T 1E2 Canada
    J Virol 85:2828-36. 2011
    ..Hence, the capacity of HIV-1 to modulate MHC-I is not linked to its ability to integrate. Thus, Nef-mediated evasion of host immune responsiveness might be attributable, in part at least, to transcription from unintegrated viral DNA...
  99. pmc Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes
    Eugene L Asahchop
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    Antimicrob Agents Chemother 55:600-7. 2011
    ..We identified K101Q, E138K, V179E, V189I, G190E, and H221Y as mutations not included among the 17 currently recognized resistance-associated mutations for ETR...
  100. ncbi request reprint Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C
    Yudong Quan
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada
    AIDS Res Hum Retroviruses 19:743-53. 2003
    ..Subtype C variants containing the novel V106M resistance codon showed cross-resistance to all approved NNRTIs in cell-free RT assays...
  101. pmc In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1
    Serge Dandache
    Ambrilia Biopharma, Inc, 1000 Chemin du Golf, Verdun, Quebec, Canada H3E 1H4
    Antimicrob Agents Chemother 51:4036-43. 2007
    ..These data underscore the potential for PL-100 to be used in the treatment of drug-resistant HIV disease and argue for its further development...

Research Grants4

  1. DELETION MUTAGENESIS WITHIN NONCODING SEGMENTS OF HIV1
    Mark Wainberg; Fiscal Year: 2001
    ..6. To determine whether these attenuated SIV constructs may protect against subsequent challenge with virulent forms of SIV and SIV/HIV hybrids. ..